Adicet Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Adicet Bio, Inc. (ACET) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $19.75 per share as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2026-08-05
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $19.75.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $21.27.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $40.23.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $2.53.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $19.75 10-Q · filed 2026-08-05 |
| 2026-03-31 | $21.27 10-Q · filed 2026-05-13 |
| 2025-12-31 | $40.23 10-K · filed 2026-03-12 |
| 2025-09-30 | $2.53 10-Q · filed 2025-11-05 |
| 2025-06-30 | $2.56 10-Q · filed 2025-08-07 |
| 2025-03-31 | $2.60 10-Q · filed 2025-05-06 |
| 2024-12-31 | $3.09 10-K · filed 2025-03-06 |
| 2024-09-30 | $3.12 10-Q · filed 2024-11-06 |
| 2024-06-30 | $7.14 10-Q · filed 2024-08-13 |
| 2024-03-31 | $8.44 10-Q · filed 2024-05-14 |
| 2023-12-31 | $10.64 10-K · filed 2024-03-19 |
| 2023-09-30 | $10.74 10-Q · filed 2023-11-08 |
| 2023-06-30 | $12.41 10-Q · filed 2023-08-09 |
| 2023-03-31 | $12.82 10-Q · filed 2023-05-09 |
| 2022-12-31 | $14.44 10-K · filed 2023-03-15 |
| 2022-09-30 | $14.23 10-Q · filed 2022-11-08 |
| 2022-06-30 | $14.16 10-Q · filed 2022-08-10 |
| 2022-03-31 | $14.24 10-Q · filed 2022-05-12 |
| 2021-12-31 | $14.08 10-K · filed 2022-03-15 |
| 2021-09-30 | $13.10 10-Q · filed 2021-11-10 |
| 2021-06-30 | $12.90 10-Q · filed 2021-08-12 |
| 2021-03-31 | $12.79 10-Q · filed 2021-05-17 |
| 2020-12-31 | $10.90 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |